Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
Vaccines (2022) - Comments
pubmed: 36366373  doi: 10.3390/vaccines10111865  issn: 2076-393x 

Mine Durusu Tanriover, Ozlem Altuntas Aydin, Rahmet Guner, Orhan Yildiz, Ilhami Celik, Hamdi Levent Doganay, Sukran Kose, Sila Akhan, Emin Halis Akalin, Zafer Sezer, Aykut Ozdarendeli, Serhat Unal, On Behalf Of The Turkovac Study Group